Scroll to top

Chair’s Letter

19 September 2016

This summer our team supplied the first SCENESSE® (afamelanotide 16mg) treatment for erythropoietic protoporphyria (EPP) patients in the Netherlands and Austria. It has been a long journey and our gratitude goes to the forbearance of patients, physicians, and shareholders alike in supporting the efforts of a dedicated Clinuvel staff, who must take pride and credit for an outstanding achievement. Four months after the very final signature of the post-authorisation commitments by the European Medicines Agency, EPP patients now have, for the first time, a standard of care in Europe.

Download PDF for more

We use cookies to give you the best experience.